Chau Gar-Yang
Gar-Yang Chau, Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
World J Gastroenterol. 2014 Sep 21;20(35):12473-84. doi: 10.3748/wjg.v20.i35.12473.
The incidence of hepatocellular carcinoma (HCC) is increasing worldwide, largely due to hepatitis B virus (HBV), hepatitis C virus and liver cirrhosis. Chronic HBV infection is estimated to cause 55%-60% of the cases of HCC worldwide and over 70% in Asian countries. Liver resection is currently the mainstay of treatment due to the low surgical mortality, a wider treatment indication, and simplicity of post-treatment follow-up. There is an ever-increasing demand on surgeons to perform curative liver resection in HCC, with the hope of avoiding tumor recurrences. Hepatitis B-related-HCC has distinct clinicopathological features, which should be considered when treating the disease. The author presents a review of the recently evolving strategies and emerging therapies to improve HCC postresectional outcomes and focus on perioperative measures to improve patient outcome, with particular reference to the current status of adjuvant therapies in HCC patients after liver resection.
肝细胞癌（HCC）的发病率在全球范围内呈上升趋势，这主要归因于乙型肝炎病毒（HBV）、丙型肝炎病毒和肝硬化。据估计，慢性HBV感染导致全球55%-60%的HCC病例，在亚洲国家这一比例超过70%。由于手术死亡率低、治疗适应证更广以及治疗后随访简单，肝切除术目前是主要的治疗方法。对外科医生进行HCC根治性肝切除术的需求不断增加，以期避免肿瘤复发。乙型肝炎相关HCC具有独特的临床病理特征，在治疗该疾病时应予以考虑。作者综述了最近不断发展的策略和新兴疗法，以改善HCC切除术后的预后，并着重介绍改善患者预后的围手术期措施，特别提及肝切除术后HCC患者辅助治疗的现状。
